Pricing Availability   Qty
Cat.No. 3126 - d[Cha4]-AVP | Mpr-Tyr-Phe-Cha-Asn-Cys-Pro-Arg-Gly-NH2 | CAS No. 500170-27-4
Description: Potent and selective human V1B agonist
Citations (1)
Literature (3)

Biological Activity

Potent and selective human vasopressin V1B receptor agonist (Ki values are 1.2, 151, 240 and 750 nM for V1B, V1A, Oxytocin and V2 receptors respectively). Stimulates ACTH and corticosterone secretion and exhibits negligible vasopressor activity in vivo.

Technical Data

M. Wt 1094.31
Formula C50H71N13O11S2

(Modifications: X-1 = Mpr, X-4 = Cha, Gly-9 = C-terminal amide, Disulfide bridge between X-1 - Cys-6)

Storage Store at -20°C
CAS Number 500170-27-4
PubChem ID 44419028
Smiles NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC2CCCCC2)C(=O)N[C@@H](CC(N)=O)C(=O)N1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data

Solubility Soluble to 1 mg/ml in water

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:


References are publications that support the biological activity of the product.

Derick et al (2002) [1-Deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology 143 4655 PMID: 12446593

Cheng et al (2004) Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J.Med.Chem. 47 2375 PMID: 15084136

Pena et al (2007) Design and synthesis of the frist selective agonists for the rat vasopressin V1b receptor: based on modifications of deamino-[cys1]arginine vasopressin at positions 4 and 8. J.Med.Chem. 50 835 PMID: 17300166

If you know of a relevant reference for d[Cha4]-AVP, please let us know.

View Related Products by Product Action

View all Vasopressin Receptor Agonists

Keywords: d[Cha4]-AVP, d[Cha4]-AVP supplier, Potent, selective, human, V1b, agonists, V2, Receptors, Vasopressin, 3126, Tocris Bioscience

1 Citation for d[Cha4]-AVP

Citations are publications that use Tocris products. Selected citations for d[Cha4]-AVP include:

Perígolo-Vicente et al (2014) IL-6, A1 and A2aR: a crosstalk that modulates BDNF and induces neuroprotection. Biochem Biophys Res Commun 449 477 PMID: 24845382

Do you know of a great paper that uses d[Cha4]-AVP from Tocris? Please let us know.

Reviews for d[Cha4]-AVP

There are currently no reviews for this product. Be the first to review d[Cha4]-AVP and earn rewards!

Have you used d[Cha4]-AVP?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Peptide Hormone Receptors

Peptide Hormone Receptors Product Listing

A collection of over 200 products for peptide hormone receptors, the listing includes research tools for the study of:

  • Anterior Pituitary Regulation
  • Blood Pressure Regulation
  • Feeding and Appetite Regulation
  • Glucose Regulation
  • Peptide Hormone Processing

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.